Researchers at the NIH have developed a new form of tumor infiltrating lymphocyte (TIL) therapy that significantly improves treatment outcomes for patients with metastatic gastrointestinal cancers.
- This personalized cancer immunotherapy involves selecting and cultivating immune cells from the tumor.
- Patients in the trial received TILs plus pembrolizumab (Keytruda), resulting in a tumor size reduction in nearly 24% of cases.
- Only 7.7% showed improvement with TILs alone.
This advancement offers new hope for treating solid tumors with cell-based therapies.
Tags #Technology
Want to read more about this ? One of the original source articles from a trusted news source (not legacy media) is here:
